Drugs / Bispecific anti-CD19, anti-CD20 CAR T cells
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07166549 | Jun 2026 → Nov 2028 expected | B-cell neoplasm, lymphoid leukemia | University Hospital, Basel, Switzerland | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bispecific anti-CD19, anti-CD20 CAR T cells | “Experimental Intervention: Bispecific anti-CD19, anti-CD20 CAR T cells” NCT07166549 ↗ |
| Modality | Cell therapy | “Chimeric antigen receptor (CAR) T cells are engineered T-lymphocytes” NCT07166549 ↗ |
| Target | CD19 | “bispecific anti-CD19, anti-CD20 CAR T cells” NCT07166549 ↗ |